Get Started

BCLI

PINK Brainstorm Cell Therapeutics Inc.
Nov 12, 2026 · 5:15 PM ET LAST TRADE Market Closed

$1.00 ↑ +0.00 (+0.00%) Trading Up from the previous close of $1.00, $0.02 below the day’s high of $1.02

YTD change
+80.83%
vs 20-day SMA
+17.83%
vs 200-day SMA
+17.50%

Price ranges

Previous day
$0.8757 $0.9900
open $0.9900 close $0.9898
-$0.0002 (-0.02%)
Today
$0.95 $1.02
open $0.99 now $1.00
+$0.01 (+1.02%)
Past week
$0.70 $0.99
from $0.83 now $1.00
+$0.17 (+21.05%)
Past month
$0.70 $0.99
from $0.84 now $1.00
+$0.17 (+19.76%)
This year
$0.46 $1.69
from $0.55 now $1.00
+$0.45 (+80.83%)

Price & Performance

+0.30 (+43.45%) / 6M

$0.5652$0.8784$1.19$1.50May 12Aug 12Nov 11

Signals & Sentiment

Momentum, market sentiment, and recent alerts

Very Good
  • The stock is 99.6% away from all-time highs of $269.25
  • BCLI is up 81% since the beginning of the year
  • BCLI is up 56% over the past 12 months
  • BCLI is up 20% over the past 1 month
  • 0% of all BCLI investors are betting against BCLI

BCLI reads very good: price sits above both the 20- and 200-day averages, the 12-month move is +54.7%.

Financial Strength

Earnings, valuation, and balance sheet

Earnings

Profitable No
EPS $-0.35
Earnings momentum -94.4% Quarterly EPS growth
Quarterly change -94.4%

Valuation

P/E ratio N/A
Enterprise value $12.3M
Beta 1.00

Balance sheet & scale

IncomeN/A
RevenueN/A
Cash$22.0K
Debt$1.4K
Income / Debt N/A

Company & Peers

Company profile and competitor comparison

Company profile

ExchangePINK
Sector Professional, Scientific, and Technical Services
Industry Group Scientific Research and Development Services
Market cap $11.0M

Brainstorm Cell Therapeutics, Inc. is a biotechnology company, which develops and commercializes autologous cellular therapies for the treatment of neurodegenerative diseases, including Amyotrophic Lateral Sclerosis, Progressive Multiple Sclerosis, Alzheimer's disease, and other neurodegenerative diseases. Its pipeline, NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and improve neurological function. The company was founded by Irit Arbel on September 22, 2000 and is headquartered in New York, NY.

Competitor comparison

TickerCompany PriceChange
AMGN Amgen Inc. $468.11 +0.62%
MRNA Moderna, Inc. $248.69 -0.85%
RVMD Revolution Medicines, Inc. $180.70 -6.40%
ROIV Roivant Sciences Ltd. $41.85 +1.60%
BNTX BioNTech SE Sponsored ADR $87.65 +0.50%

You looked up one stock
Trade Ideas watches them all

Real-time scanning and AI-generated signals across the entire market.

See plans TI Pro Download

Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.